← Back to Search

Cancer Vaccine

Lymphoma Vaccine for Follicular Lymphoma

Phase 1

Waitlist Available

Led By Eric Jacobsen, MD

Research Sponsored by Dana-Farber Cancer Institute

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

35 years of age or older

Histologically confirmed follicular lymphoma

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 2 years

Awards & highlights

Study Summary

This trial is testing a new lymphoma vaccine to see if it is safe and if it boosts the immune system to better fight the cancer.

Who is the study for?

This trial is for adults over 35 with follicular lymphoma who've had a stem cell transplant at least 6 months ago and responded to recent treatment. They must have a sample of their tumor available, be in good physical condition (ECOG 0 or 1), and not be pregnant or nursing. People with uncontrolled infections, certain psychiatric conditions, HIV/hepatitis, autoimmune diseases requiring treatment, another cancer type, or those who've been in other vaccine trials can't join.Check my eligibility

What is being tested?

The study tests three doses of a personalized cancer vaccine made from the patient's own lymphoma cells modified to produce GM-CSF—a hormone that boosts immune response—against the participant's lymphoma. The goal is to see if this vaccine can enhance the body's natural defense against cancer.See study design

What are the potential side effects?

Potential side effects may include reactions at the injection site due to vaccination and immune system responses such as fever or fatigue. Since it involves stimulating the immune system, there might also be risks of inflammation or autoimmunity where the body attacks its own cells.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am 35 years old or older.

Select...

My lymphoma is confirmed to be of the follicular type.

Select...

My follicular lymphoma improved after my last treatment.

Select...

My lymphoma can be or has been sampled for vaccine preparation.

Select...

I am fully active or can carry out light work.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 2 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~2 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and 2 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

To determine the safety and toxicity of administering vaccine composed of lethally irradiated lymphoma cells admixed with GM-CSF secreting K562 cells in patients with follicular lymphoma.

Secondary outcome measures

To describe the biologic activity of the study vaccine

to determine progression free survival and overall survival.

to determine tumor overall response rate as well as complete and partial response rates

Trial Design

1Treatment groups

Experimental Treatment

Group I: Biological/VaccineExperimental Treatment1 Intervention

Biological/Vaccine: Lethally Irradiated Lymphoma cells with GM-CSF K562 Cells Dose will vary depending upon number of cells collected and when the participant is enrolled on the study: the vaccine is given as an injection under the skin once weekly for 3 weeks then every other week for 3 vaccines. --------------------------------------------------------------------------------

0 / 5Eligibility criteria met

Find a Location

Who is running the clinical trial?

Dana-Farber Cancer InstituteLead Sponsor

1,079 Previous Clinical Trials

340,908 Total Patients Enrolled

Eric Jacobsen, MDPrincipal InvestigatorDana-Farber Cancer Institute

5 Previous Clinical Trials

113 Total Patients Enrolled

Media Library

Lethally Irradiated Lymphoma cells with GM-CSF K562 Cells (Cancer Vaccine) Clinical Trial Eligibility Overview. Trial Name: NCT00487305 — Phase 1

Follicular Lymphoma Research Study Groups: Biological/Vaccine

Follicular Lymphoma Clinical Trial 2023: Lethally Irradiated Lymphoma cells with GM-CSF K562 Cells Highlights & Side Effects. Trial Name: NCT00487305 — Phase 1

Lethally Irradiated Lymphoma cells with GM-CSF K562 Cells (Cancer Vaccine) 2023 Treatment Timeline for Medical Study. Trial Name: NCT00487305 — Phase 1

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there any remaining spots available in this scientific trial?

"According to clinicaltrials.gov, this study has concluded its patient recruitment phase and is not currently looking for candidates. This trial was initially posted on June 1st 2007, with the last update occurring February 28th 2022. Nevertheless, there are still 1720 other trials actively recruiting patients at present."

Answered by AI